Compare ADMA Biologics Inc (ADMA) vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock (TTWO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock — how do they compare? ADMA Biologics Inc trades at $9.24 (market cap $2.13B), while TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock trades at $251.92 (market cap $47.86B). The key difference: TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock is far larger — about 22.5× ADMA Biologics Inc's market cap, and TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | TTWO | |
|---|---|---|
Market Cap | $2.13B | $47.86B |
Sector | Health | Media |
52-Week High | $20.38 | $262.29 |
52-Week Low | $7.60 | $189.69 |
Enterprise Value | $2.20B | $48.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Take-Two Interactive (TTWO) trades at $257.79, up 1.12% with strong bullish momentum driven by Grand Theft Auto VI pre-orders and recent earnings beats. The stock shows technical strength with bullish moving averages, though RSI indicates overbought conditions. Despite negative net income margins, revenue growth to $5.63B in 2025 and analyst consensus of $302.50 price target reflect optimism around the GTA VI launch in November 2026.
Outlook remains positive with GTA VI as a major catalyst, but risks include high debt levels and profitability challenges. Institutional sentiment is strongly bullish with 79% buy ratings, yet investors should monitor execution risks and competitive pressures in the gaming sector. The stock's valuation metrics like P/S of 7.14 suggest growth expectations are priced in.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock
Found in 1993, Take-Two consists of three wholly owned labels, Rockstar Games, 2K, and Zynga. The firm is one of the world's largest independent video game publishers on consoles, PCs, smartphones, and tablets. Take-Two's franchise portfolio is headlined by Grand Theft Auto (345 million units sold) and contains other well-known titles such as NBA 2K, Civilization, Borderlands, Bioshock, and Xcom. Zynga mobile titles include Farmville, Empires & Puzzles, and CSR Racing.
Read more on TTWO →
